Pituitary apoplexy during induction chemotherapy for acute myeloid leukaemia
Schnitzler syndrome
Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia
Cytotoxic T lymphocytes as immune-therapy in haematological practice
Virchow and his triad
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
Integrated genomic and expression profiling in mantle cell lymphoma
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia
Reduction of B cell turnover in chronic lymphocytic leukaemia
The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma
Aplastic anaemia in association with coeliac disease
Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma
A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage
Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism
Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean
Rituximab in the treatment of autoimmune haematological disorders
Rituximab in the treatment of autoimmune haematological disorders – response to Provan et al
Chronic lymphocytic leukaemia
Rituximab as treatment for minimal residual disease in hairy cell leukaemia
Functional analysis of protein Z (Arg255His) and protein Z-dependent protease inhibitor (Lys25Arg and Ser40Gly) polymorphisms
Megakaryocyte hyperproliferation without GATA1 mutation in foetal liver of a case of Down syndrome with hydrops foetalis
Corrigendum